Health technology company Hound Labs has secured $20m in capital to advance the production of its Hound marijuana breathalyser.

The funds will be used by the company to expand sales, marketing and manufacturing teams to meet the demand for the Hound marijuana breathalyser.

Led by Entourage Effect Capital (EEC), the financing round saw participation from current investors Intrinsic Capital, Benchmark and Icon Ventures. It has also included participation from Tuatara Capital, a private equity firm focused on the cannabis sector.

Hound marijuana breathalyser features a patented ultra-sensitive technology, which has the potential to isolate recent cannabis use by specifically measuring THC1, the primary psychoactive ingredient in cannabis.

Hound Labs CEO Dr Mike Lynn said: “In order to manage our supply chain and meet demand for inventory, we have been reaching out to employers on our Wait List to understand the volumes required for our commercial units in 2022.”

According to the company, the ability to determine when an employee used cannabis is crucial now, as most adults in the US can legally use recreational cannabis outside of work hours.

The cannabis detection windows by conventional drug tests are said to cause employees to test positive for days, weeks, or months after impairment has subsided.

Hound marijuana breathalyser is claimed to be the only ultra-sensitive cannabis testing solution, which detects recent use that correlates with the window of impairment.

By using the device, the employers can keep employees who might otherwise test positive through conventional cannabis tests of oral fluid, urine and hair.

Hound Labs CEO and co-founder Dr Mike Lynn said: “The response has been incredible. We are negotiating multi-million-dollar contracts with companies from a variety of industries who want to secure Hound marijuana breathalyzerS ahead of our 1Q22 commercial launch.”

Established in 2014, Hound Labs is engaged in the development of portable health solutions to improve health and wellness.